Browse studies

Find your next paid study

119 recruiting studies matching your filters

Newest first Highest paying

Phase 1

A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)+1 more

Estimated

~$10 – $8,750

Revolution Medicines, Inc.NCT05379985

Phase 2

IGNITE: A Phase 2 Study of Maintenance Combinatorial Myeloid Immunotherapy in Patients With Unresectable Pancreatic Ductal Adenocarcinoma

Phase II, open-label, single-arm study of CD40/Dectin-1 immunotherapy as maintenance treatment in patients with unresectable pancreatic ductal adenocarcinoma (…

Pancreatic Ductal Adenocarcinoma

Estimated

~$10 – $6,250

University of PennsylvaniaNCT07199764

Phase 1

Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors

This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and …

Solid Tumors With HRAS AlterationsNon Small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)+4 more

Estimated

~$10 – $8,750

Kura Oncology, Inc.NCT06026410

Phase 1

Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)+1 more

Estimated

~$10 – $8,750

Revolution Medicines, Inc.NCT06040541

Phase 2

A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWItch/Sucrose Non-Fermentable (SWI/SNF) Alterations.

This is a Phase 2 trial evaluating the combination of cemiplimab with the standard of care chemotherapy agent gemcitabine for the treatment of patients with me…

Pancreatic Ductal Adenocarcinoma (mPDAC)

Estimated

~$10 – $6,250

University of California, San DiegoNCT06790602

Phase 1

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresect…

Non-Small Cell Lung CancerNSCLCPDAC - Pancreatic Ductal Adenocarcinoma+11 more

Estimated

~$10 – $8,750

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)NCT06917079

Phase 2

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Background: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types. \[18F\]FAP…

SarcomaSmall Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC)Mesothelioma+7 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06503146

Phase 1

A Pilot Study of Zimberelimab and Quemliclustat Combination With Chemotherapy in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

This phase I/II study tests how well zimberelimab and quemliclustat work in combination with chemotherapy (mFOLFIRINOX) in treating patients pancreatic adenoca…

Borderline Resectable Pancreatic AdenocarcinomaLocally Advanced Pancreatic Ductal Adenocarcinoma

Estimated

~$10 – $6,250

Jonsson Comprehensive Cancer CenterNCT05688215

Phase 1

A Phase 1/1b Multiple Cohort Trial of ALTA3263 in Patients With Advanced Solid Tumors With KRAS Mutations

The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.

CancerPDAC - Pancreatic Ductal AdenocarcinomaNSCLC (Non-small Cell Lung Cancer)+2 more

Estimated

~$10 – $8,750

Alterome Therapeutics, Inc.NCT06835569

Phase 1

A Phase 1, Open-Label, Dose Escalation and Expansion Study of Mavrostobart (PT199) Administered Alone in Adult Patients With Advanced Solid TuMORs, in CombiNation With a Checkpoint INhibitor TreatinG Wild-type Non-Small Cell Lung Cancer, or in Combination With ChemoTherapy for Metastatic or Advanced PAncreatic Ductal AdenocaRcinoma (MORNINGSTAR)

This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary effic…

Non Small Cell Lung CancerPancreatic Ductal Adenocarcinoma

Estimated

~$10 – $8,750

Phanes TherapeuticsNCT05431270

Phase 1

A Phase 1 Study of ASP5834 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS Mutations or KRAS Amplifications

Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researc…

Solid TumorNon-Small-Cell Lung CancerPancreatic Ductal Adenocarcinoma+1 more

Estimated

~$10 – $8,750

Astellas Pharma IncNCT07094204

Phase 1

A Phase 1/2a, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BMS-986523 As Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants …

Advanced Solid MalignanciesNon-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)+1 more

Estimated

~$10 – $7,500

Bristol-Myers SquibbNCT07223047